Safety and efficacy of a formulation of a novel triple combination paint in the management of cutaneous warts

This research project aims to evaluate the safety and efficacy of a novel topical formulation combining hydrogen peroxide (10%), salicylic acid (10%), and thuja occidentalis (10%) for the treatment of cutaneous warts. The study will be conducted at the dermatology outpatient department of Saveetha Institute of Medical and Technical Sciences, Chennai, and will involve adult patients with clinically diagnosed cutaneous warts.

The primary objective is to assess the clearance of warts using the triple combination paint. Secondary objectives include measuring the time to wart clearance, recurrence rates, patient satisfaction, incidence of adverse reactions, and improvements in quality of life.

Methodology:

This prospective clinical study will enroll patients aged 18 years and above who meet the inclusion criteria and consent to participate. The topical formulation will be applied daily for a duration of 6 weeks. Safety and efficacy will be monitored through regular follow-up visits at weeks 1, 2, 4, and 6, with post-treatment follow-ups at 3 and 6 months.

Inclusion Criteria:

Adults aged 18 and above with clinically diagnosed cutaneous warts

Exclusion Criteria:

Known hypersensitivity to any component of the formulation

Pregnant or lactating women

Immunocompromised individuals

Expected Outcomes:

The study aims to demonstrate that the triple combination paint is a safe and effective treatment for cutaneous warts, with high patient satisfaction and low recurrence rates. Findings from this study could lead to the development of a new, non-invasive treatment option for cutaneous warts, benefiting both patients and the broader medical community.

Regular monitoring and thorough documentation of adverse reactions will ensure the safety of participants, while the efficacy of the treatment will be evaluated based on clinical assessments and patient feedback. The study’s findings could significantly advance dermatological therapeutics and improve patient outcomes in the management of cutaneous warts.